BD Names Bridget Bagnato Worldwide President of Peripheral Intervention

BD Names Bridget Bagnato Worldwide President of Peripheral Intervention

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Bridget Bagnato has been appointed worldwide president of its Peripheral Intervention business unit, effective November 16.

BD Names Bridget Bagnato Worldwide President of Peripheral Intervention

Based at Peripheral Intervention's headquarters in Tempe, Arizona, Bagnato will be responsible for driving the business unit's global strategic, operational and commercial performance. She will report to Peter Menziuso, executive vice president and president of the Interventional segment.

"Bridget brings deep experience across BD and a strong understanding of our customers, with a proven ability to grow businesses through innovation and operational excellence," said Menziuso. "I'm confident she will build on Peripheral Intervention's strong foundation, advancing differentiated technologies across peripheral vascular disease, oncology, and end-stage kidney disease to address significant unmet needs and deliver greater value for customers and patients."

Bagnato currently serves as worldwide president of BD's Specimen Management business unit. During her more than 27 years at the company, she has held leadership roles across a range of BD businesses, including in Medication Delivery Solutions and Surgery, where she served as vice president and general manager of Surgical Complication Solutions.

Bagnato holds a bachelor's degree from Villanova University and an MBA from The Fuqua School of Business at Duke University.

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X or Instagram @becton_dickinson.

Contacts:


Media

Investors

Matt Marcus

Shawn Bevec 

VP, Public Relations

SVP, Investor Relations

Matt.Marcus@bd.com

Investor_Relations@bd.com

BD (Becton, Dickinson and Company) Logo

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-names-bridget-bagnato-worldwide-president-of-peripheral-intervention-302928462.html

SOURCE BD (Becton, Dickinson and Company)

News Provided by PR Newswire via QuoteMedia

BDX
The Conversation (0)
Red Mountain Mining

Acquisition of “Thompson Falls” High-Grade Antimony Project Adjacent to America’s only Antimony Smelter

Red Mountain Mining Limited (ASX: RMX, US CODE: RMXFF, or “Company”), a Critical Minerals exploration and development company with an established portfolio in Tier-1 Mining Districts in the United States and Australia, is pleased to announce the Company’s newly-acquired Thompson Falls Antimony... Keep Reading...
Bcal Diagnostics Limited

BCAL Diagnostics Launches BREASTEST plus - Generating First Revenues

BCAL Diagnostics Limited (ASX: BDX) (“BCAL” or “the Company”), an Australian and US-based biotechnology company pioneering non-invasive breast cancer diagnostics, is pleased to announce the commercial launch of BREASTEST plus™. This first-in-class blood test is available from Thursday, 27 March... Keep Reading...
Bcal Diagnostics Limited

BCAL Commences US Operations

BCAL Diagnostics Limited (ASX: BDX) (“BCAL” or “the Company”) is pleased to announce that it has established a North Carolina, United States of America, incorporated wholly owned subsidiary, BCAL Diagnostics, Inc. (“BCAL US”) which will commence operations on 2 September 2024.... Keep Reading...
TSXV:SYH

Skyharbour Signs Option Agreement with Black Shield Metals Corp to Option 75% of the Mann Lake Uranium Project

Skyharbour Resources Ltd. (TSX-V: SYH ) (OTCQB: SYHBF ) (Frankfurt: SC1P ) ("Skyharbour" or the "Company") is pleased to announce that it has entered into an option agreement (the "Option Agreement") with Black Shield Metals Corp. (CSE: BDX) ("Black Shield") which provides Black Shield an... Keep Reading...
vegn stock cse

CSE Reports April 2021 Market Statistics

CSE is increasingly the exchange of choice for successful entrepreneursThe Canadian Securities Exchange ("CSE" or "the Exchange") today announced its market statistics for the month of April 2021. Trading volume exceeded three billion shares, while the total capital raised by issuers exceeded $1... Keep Reading...

Interactive Chart

Latest Press Releases

Related News